Corcept Therapeutics, Inc.

Biotech Stock Mailbag: Corcept Therapeutics, Reader Retorts

Corcept Therapeutics rises 6%

Corcept Therapeutics Korlym has good chance to be approved, says Stifel Nicolaus

Catalysts On Tap For Corcept Therapeutics

Corcept Therapeutics Korlym well-positioned to be approved, says JMP Securities

Summer Street's pharmaceuticals analyst research team holds conference call

Corcept Therapeutics - What's Ahead?

Play TheStreet's FDA Drug-Approval Contest

Corcept Therapeutics (CORT) Get Boost From Leerink Swann Upgrade - Positive Ahead of PDUFA Date for Korlym

Corcept Therapeutics upgraded to Outperform from Market Perform at Leerink

BioLogic Equity Research Starts Corcept Therapeutics (CORT) at Sell

Corcept Therapeutics February 17 PDUFA date previewed at Leerink

27 Hot Drugs Facing FDA Approval in 2012

FDA Requires No REMS Program for Corcept's (CORT) Korlym

FDA will not require risk evaluation in Corcept's distribution of Korlym

FDA Will Not Require a Risk Evaluation and Mitigation Strategy in Connection With Corcept's Proposed Distribution of Korlym(TM) for Cushing's Syndrome

Corcept Therapeutics reports Q3 EPS (8c) vs. consensus (10c)

Corcept Therapeutics Announces Third Quarter Results and Corporate and Development Update

Piper Jaffray's biotech and specialty pharma analysts hold a conference call

Corcept Therapeutics management to meet with Oppenheimer

No US FDA AdCom for Corcept's Cushing's drug

Corcept hires new chief financial officer

FDA: No advisory meeting needed for Corcept drug

Corcept names Gary Robb finance chief

FDA Dismisses Advisory Committee Meeting for Corcept Therapeutics (CORT) New Drug Application for CORLUX

Corcept (CORT) Appoints Gary Robb as CFO

Gary C. Robb joins Corcept Therapeutics as CFO

No FDA Advisory Committee Meeting Planned in Connection With New Drug Application for CORLUX for Cushing's Syndrome

McNicoll, Lewis & Vlak Reiterates Corcept Therapeutics Buy, $8 PT

Corcept Therapeutics reports Q2 EPS (11c) vs. consensus (9c)

Corcept Therapeutics Announces Second Quarter Results and Corporate and Development Update

Oppenheimer Initiates Corcept Therapeutics At Outperform, $8 PT

Corcept Therapeutics management to attend a meeting hosted by Global Hunter

Corcept Therapeutics management to attend meetings hosted by Global Hunter

FDA accepts application from Corcept for Cushing’s Syndrome drug

Corcept Therapeutics falls 8%

Corcept Therapeutics (CORT) sees heavy pressure

Corcept says FDA accepts its Corlux application

FDA Accepts Submission of New Drug Application for CORLUX for Cushing's Syndrome

FDA accepts submission of new Corcept drug application for CORLUX